EP1119353A1 - Compositions and methods of inhibiting neoplastic diseases with compounds related to limocitrin and 5-desmethyl sinensetin - Google Patents
Compositions and methods of inhibiting neoplastic diseases with compounds related to limocitrin and 5-desmethyl sinensetinInfo
- Publication number
- EP1119353A1 EP1119353A1 EP99950209A EP99950209A EP1119353A1 EP 1119353 A1 EP1119353 A1 EP 1119353A1 EP 99950209 A EP99950209 A EP 99950209A EP 99950209 A EP99950209 A EP 99950209A EP 1119353 A1 EP1119353 A1 EP 1119353A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- limocitrin
- administering
- carcinoma
- effective amount
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention relates to compositions and methods for the prevention
- the present invention also relates to compositions and methods for the prevention and treatment of atherosclerosis, thrombosis, inflammatory diseases, allergies or viral diseases. These compounds are a group of naturally occurring
- limocitrin-derived compounds 3,5,7,4'-tetramethoxylimocitrin, 3,7,4'-trimethoxylimocitrin,
- Limocitrin analogues are a group of citrus-derived flavonoids that are naturally
- 5-desmethoxy sinensetin is chemically
- Flavonoids are polyphenolic compounds that
- flavonoids occur ubiquitously in foods of plant origin.
- the major dietary sources of flavonoids are
- Plants have evolved flavonoids as protection against parasites, herbivores, and
- flavonoids contribute to the color of fruits
- dietary flavonoids in the United States has been estimated at lg/day expressed as glycosides, of which about 170 mg expressed as aglycones, consist of flavonols, flavonones and flavones (Kuhnau, J., 1976, World Rev. Nutr. Diet 24:fl 17-191). Flavonol and flavone intake thus exceeds that of other dietary antioxidants such as beta-carotene (2-3mg/day) and vitamin E (7-10mg/day) and equals approximately one-third of vitamin C (70-100mg/day) (Nutrient intakes. Individuals in 48 states. Year 1977-1978. Report No. 1-2. Consumer Nutrition
- Flavonoids have been demonstrated to be the most potent dietary antioxidants and in light of
- flavonoids make a major contribution to the antioxidant
- the main food sources of flavonols and flavones are black tea,
- Flavonol and flavone intake was inversely associated with mortality from coronary heart disease and to a lesser
- Flavonol and flavone intake (mainly quercetin) was also inversely associated with stroke risk (Hertog,
- antithrombotic, anticoronary heart disease, antimyocardial infarction and/or antistroke agents are examples of antithrombotic, anticoronary heart disease, antimyocardial infarction and/or antistroke agents.
- Chemotherapeutic agents share one characteristic: they are usually more effective in killing or damaging malignant cells than normal cells. However, the fact that they do harm normal cells indicates their potential toxicity. Animal tumor investigations and human clinical trials have shown that drug combinations produce higher rates of objective response and longer survival than
- Combination drug therapy is, therefore, the basis for most chemotherapy employed at present (DeVita, V.T. et al., 1995, Cancer 35:98).
- Cancer treatment requires inhibition of a variety of factors including tumor cell
- neoplastic cells especially in disease states such as breast cancer.
- the present invention is directed to a method for the prevention and/or
- the present invention is also directed to a method for the prevention and/or
- the present invention is also directed to a method for the prevention and/or treatment of atherosclerosis, myocardial infarction, stroke or thrombosis, which involves
- the present invention is further directed to a method for inducing anti-
- the present invention is directed to the use of limocitrin analogues and 5-
- the present invention is directed to a method for the prevention and/or
- the present invention is also directed to a method for inhibiting the oxidation of low-density lipoproteins and platelet aggregation and adhesion, which involves using an
- the present invention is also directed to a method of administering an
- the method of the invention involves administering an effective dose of a one or a combination of limocitrin analogues and 5-desmethyl sinensetin, tamoxifen or a chemotherapeutic agent, in an individual who is identified as being at enhanced risk for
- cancer and/or as having cancer, in order to prevent and/or treat cancer.
- the method of the invention also involves administering an effective dose of limocitrin analogues and 5-desmethyl sinensetin to an individual who is identified as being at
- myocardial infarction or thrombosis in order to prevent and treat coronary heart diseases.
- Cancer can be viewed as a
- a cell acquires the ability to "override' these signals and to proliferate under conditions in which normal cells would not grow.
- the tumor must acquire vasculature to
- a threefold to fourfold increase in risk for breast cancer include (1) first-degree female family
- chemo-therapeutic agent has not been reported for the prevention and treatment of neoplastic
- nutraceuticals or considered as foods or parts of foods but which provide health benefits.
- the methoxylated flavones are anticipated to have very low cytotoxicity,
- flavones show very low toxicity compared with polyhydroxylated flavones.
- methoxylated and ethoxylated limocitrin analogues and 5-desmethyl sinensetin of the present invention will also have this important advantage over other dietary anti-cancer flavonoids.
- the present invention provides a number of different limocitrin compounds
- the present invention further provides the structurally-related compound, 5-desmethyl
- sarcomas and carcinomas include, but are not limited to, human sarcomas and carcinomas, e.g. carcinomas, e.g., colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chondroma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma,
- carcinomas e.g., colon carcinoma
- pancreatic cancer breast cancer, ovarian cancer, prostate cancer
- fibrosarcoma myxosarcoma
- liposarcoma liposarcoma
- osteogenic sarcoma chondroma
- angiosarcoma endo
- rhabdomyosarcoma squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat
- gland carcinoma sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal
- carcinoma Wilms' tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung
- carcinoma bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma,
- craniopharyngioma ependymoma, pinealoma, hemangioblastoma, acoustic neuroma
- oligodendroglioma meningioma, melanoma, neuroblastoma, retinoblastoma; leukemias, e.g.,
- acute lymphocytic leukemia and acute myelocytic leukemia myeloblastic, promyelocytic,
- myelomonocytic, monocytic and erythroleukemia myelomonocytic, monocytic and erythroleukemia
- chronic leukemia chronic myelocytic (granulocytic) leukemia and chronic lymphocytic leukemia
- polycythemia vera myelomonocytic, monocytic and erythroleukemia
- chronic leukemia chronic myelocytic (granulocytic) leukemia and chronic lymphocytic leukemia
- polycythemia vera polycythemia vera
- lymphoma Hodgkin's disease and non-Hodgkin's disease
- multiple myeloma Waldenstrom's
- macroglobulinemia and heavy chain disease. Specific examples of such cancers are described in the sections below.
- age elevated plasma cholesterol level, high arterial blood pressure, cigarette smoking, reduced high-density lipoprotein (HDL) cholesterol level, or family history of premature coronary artery disease.
- HDL high-density lipoprotein
- Elevation of HDL or alpha fraction has a negative correlation with
- HDL exerts a protective
- LDL cholesterol levels should have a measurement of LDL. LDL cholesterol levels are then classified as borderline-
- LDL levels greater than 189 mg/dl and for those patients with LDL cholesterol levels between 159 and 189 mg/dl who have two or more additional risk factors.
- drugs that have been used to reduce serum cholesterol levels are cholestyramine, colestipol, clofibrate, gemfibrozil and lovastatin.
- Flavonoids inhibit platelet aggregation and adhesion ( Frankel, E.N. et al., 1993,
- Flavonoids antagonize thromboxane formation and increase platelet
- the medical therapy includes, but is not limited
- beta-adrenergic blocking agents e.g., propranonol, nadolol, timolol, etc.
- nitrates e.g., nitroglycerin
- calcium channel blockers e.g., calcium channel blockers
- Limocitrin occurs in the
- peel of lemon as limocitrin-3-0-glucoside and can be produced from the 3-glucoside by
- the present invention provides a number of different analogues of limocitrin
- Flavonoids share the common skeleton of diphenylpyrans, e.g., two benzene
- Compounds structurally related to limocitrin and 5-desmethyl sinensetin may be formulated into pharmaceutical preparations for administration to humans for prevention and treatment of neoplastic diseases and/ or cardiovascular disease, atherosclerosis,
- the therapeutic compounds or pharmaceutical compositions may be administered intravenously, intraperitoneally, subcutaneously, intramuscularly, intrathecally,
- Formulations suitable for oral administration include liquid solutions of the
- active compound dissolved in diluents such as saline, water or PEG 400; capsules or tablets,
- Formulations suitable for parenteral administration include aqueous and non-
- aqueous isotonic sterile solutions which contain buffers, antioxidants and preservatives.
- the formulations may be in unit dose or multi-dose sealed containers.
- Patient dosages for oral administration of limocitrins range from 1-1000 mg/day. commonly 1-500 mg/day, and typically from 1-100 mg/day. Stated in terms of
- Dosage amount and interval may be adjusted individually to provide plasma
- a variety of delivery systems for the pharmacological compounds may be
- compositions also may comprise suitable solid or gel phase carriers or excipients.
- Such carriers or excipients include, but are not limited to, calcium carbonate, calcium
- phosphate various sugars, starches, cellulose derivatives, gelatin, and polymers such as
- liposomes for example, in a liposome coated with tumor-specific antibody.
- the liposomes will be targeted to and taken up selectively by the tumor.
- concentration of the drug may not be related to plasma concentration.
- Thymidine was purchased from ICN, Irvine, CA.
- MDA-MB-435 estrogen receptor-negative human breast cancer cells were maintained at 37°C in a minimum essential medium, supplemented with 10% (v/v) fetal bovine serum. The medium was equilibrated with a humidified atmosphere of 5% CO 2 . Stock cultures were seeded at a density of 2 x 10 4 cells/ml and allowed to multiply for 48 to 72 hours.
- MCF-7 estrogen receptor-positive human breast cancer cells were routinely maintained in minimum essential medium supplemented with 10% (v/v) fetal calf serum, 1 mM sodium pyruvate, lO ⁇ g/ml bovine insulin and 1% (v/v) antibiotic-antimycotic agents (10,000 units/ml penicillin G sodium, 10,000 ⁇ g/ml streptomycin sulfate and 25 ⁇ g/ml amphtericin B in 0.85% saline). Cells were grown to confluence at 37°C in a humidified atmosphere containing 5% CO in air and were passaged weekly, using 2% trypsin in citrate saline.
- MDA-MB-435 cells were plated at 2 x 10 4 cells/well in 96-well, flat bottomed
- the cells were harvested onto a glass fiber filter paper using a semiautomatic 12-well cell
- the MCF-7 cells were seeded at a density of 2 x 10 4 cells/well in 96- well, flat bottomed tissue culture plates and were incubated at 37°C for 5 days.
- Viability of cells was measured by MTT assay (Hansen, M.B. et al., J. Imm.
- MDA-MB-435 cells (8xl0 4 /well) were seeded with
- Results are the average of 3 experiments.
- the two synthetic analogues, limocitrin 3,5,7,4'-tetraethyl ether and limocitrin 3,7,4'-trimethyl ether 5-acetate were the two synthetic analogues, limocitrin 3,5,7,4'-tetraethyl ether and limocitrin 3,7,4'-trimethyl ether 5-acetate.
- trimethoxylimocitrin was the least effective having an IC 50 of 3.1 ppm in ER- cells and 0.5 in
- ER+ cells (Table 1). Tamoxifen, a drug widely used for the treatment of ER+ tumors has an
- limocitrin compounds are potent inhibitors of both ER- and ER+ cells and are less likely to
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16763498A | 1998-10-06 | 1998-10-06 | |
US167634 | 1998-10-06 | ||
PCT/US1999/023238 WO2000019998A1 (en) | 1998-10-06 | 1999-10-05 | Compositions and methods of inhibiting neoplastic diseases with compounds related to limocitrin and 5-desmethyl sinensetin |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1119353A1 true EP1119353A1 (en) | 2001-08-01 |
EP1119353A4 EP1119353A4 (en) | 2002-08-28 |
Family
ID=22608155
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP99950209A Withdrawn EP1119353A4 (en) | 1998-10-06 | 1999-10-05 | Compositions and methods of inhibiting neoplastic diseases with compounds related to limocitrin and 5-desmethyl sinensetin |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1119353A4 (en) |
JP (2) | JP2003509334A (en) |
AU (1) | AU6291699A (en) |
CA (1) | CA2346333A1 (en) |
WO (1) | WO2000019998A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6413533B1 (en) * | 1998-05-07 | 2002-07-02 | The University Of Tennessee Research Corporation | Method for chemoprevention of prostate cancer |
US6987125B1 (en) | 1998-10-06 | 2006-01-17 | The United States Of America As Represented By The Secretary Of Agriculture | Compositions and methods of treating, reducing and preventing cardiovascular diseases and disorders with polymethoxyflavones |
US20060135445A1 (en) * | 2003-02-04 | 2006-06-22 | Kabushiki Kaisha Yakult Honsha | Breast cancer-resistant protein inhibitor |
JP2008513350A (en) * | 2005-05-24 | 2008-05-01 | ケージーケー シナジャイズ インコーポレイテッド | Composition comprising flavonoid and tocotrienol and method thereof |
WO2008035208A2 (en) * | 2006-05-19 | 2008-03-27 | Kgk Synergize Inc | The use of flavonoids for the inhibition of cellular growth |
CN102731459B (en) * | 2012-06-15 | 2014-05-28 | 南京中医药大学 | Scutellarin aglycone Mannich derivatives, and preparation method and application thereof |
US9132117B2 (en) | 2013-06-17 | 2015-09-15 | Kgk Synergize, Inc | Compositions and methods for glycemic control of subjects with impaired fasting glucose |
KR20230161639A (en) * | 2022-05-19 | 2023-11-28 | 제주대학교 산학협력단 | Anti cancer composition containing an extract of artemisia princeps |
CN115813991A (en) * | 2022-11-29 | 2023-03-21 | 三峡大学 | Application of citrus fruit extract in preparation of medicine for treating breast cancer endocrine |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3867541A (en) * | 1972-05-03 | 1975-02-18 | Ralph C Robbins | Compositions and methods for disaggregating blood cells |
US3903266A (en) * | 1972-05-03 | 1975-09-02 | Ralph C Robbins | Compositions and methods for disaggregating blood cells |
JPH0617304B2 (en) * | 1982-09-09 | 1994-03-09 | 理化学研究所 | Anti-cancer drug |
JPH06116164A (en) * | 1992-10-07 | 1994-04-26 | Otsuka Pharmaceut Co Ltd | Chemotherapeutic agent useful for cancer in combined chemotherapy therefor |
ZA941290B (en) * | 1993-02-26 | 1995-08-25 | Res Dev Foundation | Combination cisplatin/tamoxifen therapy for human cancers |
US5336685A (en) * | 1993-04-12 | 1994-08-09 | Sloan-Kettering Institute For Cancer Research | Use of flavonoids to treat multidrug resistant cancer cells |
JPH08310952A (en) * | 1995-03-16 | 1996-11-26 | Takeda Chem Ind Ltd | Medicine composition |
AU7602896A (en) * | 1995-11-07 | 1997-05-29 | Eli Lilly And Company | Methods for treating resistant tumors |
-
1999
- 1999-10-05 EP EP99950209A patent/EP1119353A4/en not_active Withdrawn
- 1999-10-05 JP JP2000573358A patent/JP2003509334A/en not_active Withdrawn
- 1999-10-05 CA CA002346333A patent/CA2346333A1/en not_active Abandoned
- 1999-10-05 WO PCT/US1999/023238 patent/WO2000019998A1/en not_active Application Discontinuation
- 1999-10-05 AU AU62916/99A patent/AU6291699A/en not_active Abandoned
-
2004
- 2004-05-26 JP JP2004156046A patent/JP2005015469A/en active Pending
Non-Patent Citations (2)
Title |
---|
GUTHRIE N ET AL: "INHIBITION OF MAMMARY CANCER BY CITRUS FLAVONOIDS" ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY, SPRING ST., NY, US, vol. 439, 1998, pages 227-236, XP000995351 ISSN: 0065-2598 * |
See also references of WO0019998A1 * |
Also Published As
Publication number | Publication date |
---|---|
AU6291699A (en) | 2000-04-26 |
CA2346333A1 (en) | 2000-04-13 |
WO2000019998A1 (en) | 2000-04-13 |
EP1119353A4 (en) | 2002-08-28 |
JP2005015469A (en) | 2005-01-20 |
JP2003509334A (en) | 2003-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6251400B1 (en) | Compositions and methods of treatment of neoplastic diseases and hypercholesterolemia with citrus limonoids and flavonoids and tocotrienols | |
US6239114B1 (en) | Compositions and methods for treatment of neoplastic diseases with combinations of limonoids, flavonoids and tocotrienols | |
US6410061B1 (en) | Tea catechins as cancer specific proliferation inhibitors | |
Codoñer-Franch et al. | Citrus as functional foods. | |
Wiseman | The bioavailability of non-nutrient plant factors: dietary flavonoids and phyto-oestrogens | |
US6410052B1 (en) | Tea catechins in sustained release formulations as cancer specific proliferation inhibitors | |
US20090163581A1 (en) | Pharmaceutical Products for Treating Neoplastic Disease and Inflammation | |
US20010055627A1 (en) | Compositions And Methods For Regulating Lipoproteins And Hypercholesterolemia With Limonoids, Flavonoids And Tocotrienols | |
Jeong et al. | Anti-cancer effects of polyphenolic compounds in epidermal growth factor receptor tyrosine kinase inhibitor-resistant non-small cell lung cancer | |
WO2006132879A2 (en) | Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols | |
US7683095B2 (en) | Compositions and methods of treating, reducing and preventing cardiovascular diseases and disorders with polymethoxyflavones | |
Ping et al. | Taxol synergizes with antioxidants in inhibiting hormal refractory prostate cancer cell growth | |
WO2000019998A1 (en) | Compositions and methods of inhibiting neoplastic diseases with compounds related to limocitrin and 5-desmethyl sinensetin | |
Karthika et al. | Incorporation of natural assumption to deal with cancer | |
WO2005058340A1 (en) | Compositions and methods based on synergies between capsicum extracts and tea catechins for prevention and treatment of cancer | |
CN109350613A (en) | A kind of curcumin compound preparation for the treatment of cancer | |
WO2001070029A1 (en) | Compositions and methods of treating, reducing, and preventing cardiovascular diseases and disorders with polymethoxyflavones | |
US20070184132A1 (en) | Methods of treating canine osteosarcoma | |
Verma et al. | Colon Cancer Prevention by Medicinal Plants | |
Manthey et al. | Guthrie et al. | |
Jones | Effects of β-ionone on prostate cancer cells | |
Ridzuan et al. | Vitamin E isomers and cancer research: A review | |
Juturu et al. | Heart Protective Nutrients: Controversy and Evidence | |
Azadi | Investigation of the Effects of Genistein and Fenretinide on Ovarian Cancer Cells | |
KR20160049078A (en) | Pharmaceutical Compositions for Prevention or Treatment of nonalcoholic fatty liver disease Comprising Quercetin-3-O-glucoside |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20010419 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20020711 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20030718 |